Skip to Main Content

++

INTRODUCTION

++

lansoprazole (lan-soe-pra-zole)

Prevacid

Classification

Therapeutic: antiulcer agents

Pharmacologic: proton-pump inhibitors

++
Indications
++

Erosive esophagitis. Duodenal ulcers (with or without anti-infectives for Helicobacter pylori). Active benign gastric ulcer. Short-term treatment of symptomatic GERD. Healing and risk reduction of NSAID-associated gastric ulcer. Pathologic hypersecretory conditions, including Zollinger-Ellison syndrome.

++
Action
++

Binds to an enzyme in the presence of acidic gastric pH, preventing the final transport of hydrogen ions into the gastric lumen. Therapeutic Effects: Diminished accumulation of acid in the gastric lumen, with lessened acid reflux. Healing of duodenal ulcers and esophagitis.

++
Adverse Reactions/Side Effects
++

CNS: dizziness, headache. GI: diarrhea, abdominal pain, nausea. Derm: rash.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Monitor improvements in GI symptoms (gastritis, heartburn, and so forth) to help determine if drug therapy is successful.

  • Assess dizziness that might affect gait, balance, and other functional activities (See Appendix C). Report balance problems and functional limitations to the physician, and caution the patient and family/caregivers to guard against falls and trauma.

++
Interventions
++

  • In cases of NSAID-induced gastritis, implement appropriate manual therapy techniques, physical agents, and therapeutic exercises to reduce pain and decrease the need for aspirin and other NSAIDs.

++
Patient/Client-Related Instruction
++

  • Advise patient to avoid alcohol and foods that may cause an increase in GI irritation.

  • Instruct patient to report bothersome or prolonged side effects, including headache, skin rash, or GI effects (nausea, diarrhea, abdominal pain).

++
Pharmacokinetics
++

Absorption: 80% absorbed after oral administration.

++

Distribution: Unknown.

++

Protein Binding: 97%.

++

Metabolism and Excretion: Extensively metabolized by the liver to inactive compounds. Converted intracellularly to at least two other antisecretory compounds.

++

Half-life: Children: 1.2–1.5 hr; Adults: 1.3–1.7 hr (↑ in geriatric patients and patients with impaired hepatic function).

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (acid suppression)

ROUTE ONSET PEAK DURATION
PO rapid 1.7 hr >24 hr

++
Contraindications/Precautions
++

Contraindicated in: Hypersensitivity.

++

Use Cautiously in: Geri: Maintenance dose should not exceed 30 mg/day unless additional acid suppression is required; SoluTabs contain aspartame; use caution when used in phenylketonurics; Severe hepatic impairment (not to exceed 30 mg/day in these patients); OB/Lactation/Pedi: Pregnancy, lactation, or children <1 yr (safety not established).

++
Interactions
++

Drug-Drug: Sucralfate ↓ absorption of lansoprazole (take 30 min before sucralfate). May ↓ absorption of drugs requiring acid pH, including ketoconazole, itraconazole, atazanavir, ampicillin esters, iron salts, and digoxin. May ↑ risk of bleeding with warfarin (monitor INR/PT).

++
Route/Dosage
++

PO (Adults and Children ≥12 ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.